Clinical trial
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary…
NCT00287729 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00287729 |
|---|---|
| Title | Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | Pirfenidone, Placebo |
| Enrollment | 344 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 7, 2006 |
| Last update posted | Apr 17, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: